Name Brand Drug Cos. Ax Labeling Claims In Zantac MDL
By Emily Field (January 11, 2021, 8:52 PM EST) -- A Florida federal judge presiding over sprawling multidistrict litigation involving the carcinogens found in the heartburn medication Zantac cut more claims on Friday from the litigation, holding that design defect claims are barred by federal law.
U.S. District Judge Robin L. Rosenberg said that state design defect claims against name-brand Zantac manufacturers, like Pfizer Inc. and Sanofi-Aventis U.S. LLC, are preempted by the Federal Food Drug and Cosmetic Act because it was impossible for the companies to change the drug's formulation without the approval of the U.S. Food and Drug Administration.
The judge rejected arguments by consumers and third-party payers that...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!